Aura Biosciences Inc
aurabiosciences.comAura Biosciences (NASDAQ: AURA) is a clinical-stage oncology company developing virus-like drug conjugate (VDC) therapies targeting tumors while preserving organ function. The company has generated no product revenue since its founding in 2009, funding operations through equity issuances including an at-the-market facility under a $350.0 million shelf registration filed March 27, 2024. Its lead candidate, bel-sar, is in clinical development for ocular oncology indications and urologic oncology, initially non-muscle-invasive bladder cancer. Net losses were $106.2 million for the year ended December 31, 2025 and $86.9 million for the year ended December 31, 2024, with an accumulated deficit of $480.4 million as of December 31, 2025. The company has no approved products, no commercial sales organization, and no revenue-generating partnerships disclosed in the filing. Bel-sar targets modified heparan sulfate proteoglycans expressed on tumors, a mechanism the company describes as virus-like drug conjugate technology.
Products & Services
Lead asset bel-sar is a virus-like drug conjugate (VDC) in clinical development for ocular oncology and non-muscle-invasive bladder cancer (NMIBC). VDCs bind to modified heparan sulfate proteoglycans (mHSPGs) on tumor cells. No products are approved or commercialized as of the filing date.
Revenue Model
No product revenue has been generated as of the filing date. The company has funded operations through equity capital markets, including $6.7 million in gross proceeds from 1,055,362 shares issued under an at-the-market facility during the year ended December 31, 2025. Future revenue, if any, is expected from product sales or milestone and royalty payments from potential licensing or collaboration agreements, none of which are currently in place per the filing.
Customers & Markets
Target end markets are ocular oncology and urologic oncology, specifically bladder cancer. The global bladder cancer market is cited in the filing as expected to exceed $8.0 billion by 2032. End customers would be patients and prescribing physicians in oncology settings. No commercial customers exist as of the filing date.
Geographic Exposure
The company is subject to U.S. and EU regulatory frameworks based on disclosures in the filing. No specific geographic revenue breakdown is applicable given zero product revenue.
Financial Snapshot
Loading...
